Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 556099109 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Armistice Capital, LLC
13G/A
Amendment 8
|
7.9% |
8/14/2026
Event 6/30/2026
|
|
| Armistice Capital, LLC | 7.9% | ||
| Steven Boyd | 7.9% | ||
| Bank of America Corp /DE/ 13G/A Amendment 1 | 4.0% |
8/3/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G | 7.1% |
7/29/2026
Event 6/30/2026
|
|
|
Millennium Management LLC
13G/A
Amendment 1
|
3.7% |
7/20/2026
Event 6/30/2026
|
|
| Millennium Management LLC | 3.7% | ||
| Millennium Group Management LLC | 3.7% | ||
| Israel A. Englander | 3.7% | ||
|
Millennium Management LLC
13G
|
5.4% |
6/5/2026
Event 6/1/2026
|
|
| Millennium Management LLC | 5.4% | ||
| Millennium Group Management LLC | 5.4% | ||
| Israel A. Englander | 5.4% | ||
|
Armistice Capital, LLC
13G/A
Amendment 7
|
9.5% |
5/15/2026
Event 3/31/2026
|
|
| Armistice Capital, LLC | 9.5% | ||
| Steven Boyd | 9.5% | ||
|
Millennium Management LLC
13G
|
4.8% |
5/14/2026
Event 5/8/2026
|
|
| Millennium Management LLC | 4.8% | ||
| Millennium Group Management LLC | 4.8% | ||
| Israel A. Englander | 4.8% | ||
| Bank of America Corp /DE/ 13G | 5.1% |
5/14/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 6 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Armistice Capital, LLC
13G/A
Amendment 6
|
10.0% |
2/17/2026
Event 12/31/2025
|
|
| Armistice Capital, LLC | 10.0% | ||
| Steven Boyd | 10.0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 2
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 0% | ||
| FHMLSP, L.P. | 0% | ||
| FHMLSP, L.L.C. | 0% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences XI, L.P. | 0% | ||
| FHMLS XI, L.P. | 0% | ||
| FHMLS XI, L.L.C. | 0% | ||
| James N. Topper | 0% | ||
| Patrick J. Heron | 0% | ||
|
Bellevue Group AG
13G/A
Amendment 1
|
0% |
1/6/2026
Event 12/5/2025
|
|
| Bellevue Group AG | 0% | ||
| Bellevue Asset Management AG | 0% | ||
| Wasatch Advisors LP 13G/A Amendment 1 | 3.1% |
11/12/2025
Event 9/30/2025
|
|
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
2.5% |
8/14/2025
Event 6/30/2025
|
|
| Frazier Life Sciences Public Fund, L.P. | 2.5% | ||
| FHMLSP, L.P. | 2.5% | ||
| FHMLSP, L.L.C. | 2.5% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.5% | ||
| FHMLSP Overage, L.P. | 1.5% | ||
| FHMLSP Overage, L.L.C. | 1.5% | ||
| Frazier Life Sciences X, L.P. | 0.2% | ||
| FHMLS X, L.P. | 0.2% | ||
| FHMLS X, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.9% | ||
| FHMLS XI, L.P. | 0.9% | ||
| FHMLS XI, L.L.C. | 0.9% | ||
| James N. Topper | 0.2% | ||
| Patrick J. Heron | 0.2% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
| BlackRock, Inc. 13G/A Amendment 11 | 2.9% |
7/17/2025
Event 6/30/2025
|
|
|
Bellevue Group AG
13G
|
15.7% |
7/7/2025
Event 6/1/2025
|
|
| Bellevue Group AG | 15.7% | ||
| Bellevue Asset Management AG | 15.7% | ||
|
BB Biotech AG
13G/A
Amendment 11
|
0% |
6/13/2025
Event 6/1/2025
|
|
| BB Biotech AG | 0% | ||
| Biotech Target N.V. | 0% | ||
|
Armistice Capital, LLC
13G/A
Amendment 4
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Armistice Capital, LLC | 10.0% | ||
| Steven Boyd | 10.0% | ||
|
Millennium Management LLC
13G/A
Amendment 1
|
2.7% |
4/17/2025
Event 3/31/2025
|
|
| Millennium Management LLC | 2.7% | ||
| Millennium Group Management LLC | 2.7% | ||
| Israel A. Englander | 2.7% | ||
|
RA Capital Management, L.P.
13G/A
Amendment 2
|
0% |
2/14/2025
Event 12/31/2024
|
|
| RA Capital Management, L.P. | 0% | ||
| Peter Kolchinsky | 0% | ||
| Rajeev Shah | 0% | ||
| RA Capital Healthcare Fund, L.P. | 0% | ||
|
Armistice Capital, LLC
13G/A
Amendment 3
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Armistice Capital, LLC | 10.0% | ||
| Steven Boyd | 10.0% | ||
|
BB Biotech AG
13G/A
Amendment 10
|
15.8% |
2/14/2025
Event 12/31/2024
|
|
| BB Biotech AG | 15.8% | ||
| Biotech Target N.V. | 15.8% | ||
| Wasatch Advisors LP 13G | 5.6% |
2/11/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 931 | $3.59 k |
| 2026 Q2 | 128 | 48.7 M | $226 M |
| 2026 Q1 | 114 | 43.2 M | $125 M |
| 2025 Q4 | 93 | 40.0 M | $64.3 M |
| 2025 Q3 | 109 | 46.8 M | $78.7 M |
| 2025 Q2 | 118 | 48.4 M | $58.6 M |
| 2025 Q1 | 135 | 53.9 M | $68.5 M |
| 2024 Q4 | 134 | 56.1 M | $182 M |
| 2024 Q3 | 135 | 56.1 M | $189 M |
| 2024 Q2 | 162 | 61.9 M | $263 M |
| 2024 Q1 | 177 | 66.3 M | $975 M |
| 2023 Q4 | 150 | 64.0 M | $615 M |
| 2023 Q3 | 133 | 58.2 M | $271 M |
| 2023 Q2 | 136 | 60.0 M | $321 M |
| 2023 Q1 | 144 | 58.6 M | $420 M |
| 2022 Q4 | 142 | 58.1 M | $390 M |
| 2022 Q3 | 139 | 57.7 M | $200 M |
| 2022 Q2 | 136 | 62.8 M | $185 M |
| 2022 Q1 | 148 | 60.5 M | $533 M |
| 2021 Q4 | 167 | 59.0 M | $948 M |
| 2021 Q3 | 163 | 57.9 M | $1.21 B |
| 2021 Q2 | 164 | 59.5 M | $1.60 B |
| 2021 Q1 | 195 | 58.9 M | $1.87 B |
| 2020 Q4 | 157 | 55.0 M | $1.26 B |
| 2020 Q3 | 149 | 54.0 M | $1.34 B |
| 2020 Q2 | 149 | 51.5 M | $1.42 B |
| 2020 Q1 | 129 | 45.3 M | $267 M |
| 2019 Q4 | 134 | 46.4 M | $504 M |
| 2019 Q3 | 136 | 46.6 M | $595 M |
| 2019 Q2 | 151 | 47.8 M | $811 M |
| 2019 Q1 | 174 | 44.2 M | $796 M |
| 2018 Q4 | 135 | 37.2 M | $473 M |
| 2018 Q3 | 136 | 37.1 M | $796 M |
| 2018 Q2 | 129 | 38.5 M | $796 M |
| 2018 Q1 | 136 | 37.9 M | $955 M |
| 2017 Q4 | 122 | 33.6 M | $638 M |
| 2017 Q3 | 116 | 31.6 M | $583 M |
| 2017 Q2 | 117 | 31.3 M | $549 M |
| 2017 Q1 | 115 | 28.9 M | $538 M |
| 2016 Q4 | 135 | 29.2 M | $596 M |
| 2016 Q3 | 136 | 28.3 M | $846 M |
| 2016 Q2 | 129 | 28.2 M | $761 M |
| 2016 Q1 | 129 | 27.9 M | $523 M |
| 2015 Q4 | 136 | 30.5 M | $946 M |
| 2015 Q3 | 125 | 27.4 M | $597 M |
| 2015 Q2 | 129 | 21.9 M | $832 M |
| 2015 Q1 | 114 | 20.0 M | $627 M |
| 2014 Q4 | 110 | 16.8 M | $590 M |
| 2014 Q3 | 86 | 15.4 M | $323 M |
| 2014 Q2 | 90 | 15.4 M | $334 M |
| 2014 Q1 | 76 | 14.3 M | $398 M |